Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach

Drug Metabolism and Disposition - United States
doi 10.1124/dmd.116.072025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Correction to "Prediction of Drug-Drug Interactions Arising From CYP3A Induction Using a Physiologically Based Dynamic Model"

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2016English

CYP3A Probes Can Quantitatively Predict the in Vivo Kinetics of Other CYP3A Substrates and Can Accurately Assess CYP3A Induction and Inhibition

Molecular Interventions
2005English

Doravirine and the Potential for CYP3A-Mediated Drug–Drug Interactions

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy

Journal of Personalized Medicine
Medicine
2012English

A Forwards Induction Approach to Candidate Drug Selection

Advances in Applied Probability
Applied MathematicsStatisticsProbability
2011English

Strategic Approach for Drug Metabolism and Pharmacokinetic Research in the Drug Discovery Process.

Drug Metabolism and Pharmacokinetics
2001English

Specifying and Managing Tail Risk in Portfolios - A Practical Approach

SSRN Electronic Journal
2013English

It in Strategic Approach to Technology Development

Knowledge International Journal
2018English

Strategic Approach to Tourism Development in Namibia

International Journal of Sustainable Economies Management
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy